Tumor Necrosis Factor
Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Study examined patients with active rheumatoid arthritis who failed to derive benefit from or were intolerant to TNF-inhibitor therapy.
An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.
A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.
Study evaluated breast milk samples from 17 lactating mothers diagnosed with rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis.
The TNF inhibitor shows lower risk for infections and tuberculosis, according to a recent study.
Collaborative document provides guidance on non-pharmacological and pharmacological management in patients with axial spondyloarthritis.
Small study shows 20 minutes on a treadmill can decrease immune cells tied to inflammation.
The likelihood of regaining ability to work was studied in patients with rheumatoid arthritis who initiated anti-tumor necrosis factor therapy within 5 years.
Patients taking TNF-α inhibitors(TNFis) with immune mediated disease had comparable pregnancy-related outcomes to those not taking TNFis, but had significantly increased risks for adverse outcomes compared with the general population
Identifying appropriate biologic DMARDs for elderly patients with RA is becoming increasingly important.
Patients randomized to discontinuing TNFis were at increased risk of experiencing a disease flare within 12 months.
Post-hoc analysis of the FUTURE-2 trial was performed to assess if there was a differential treatment responses to secukinumab in TNFi-exposed or naïve patients with active psoriatic arthritis.
Therapeutic anti-TNF antibodies, long thought to act primarily via blockade of proinflammatory soluble TNF, appear to also bind membrane-bound TNF supporting regulatory T-cell expansion suppressing further inflammation.
Dose-optimized MTX in combination with CZP resulted in more patients achieving sustained low disease activity as compared to placebo with dose-optimized MTX in DMARD-naïve early RA.
The proportion of patients who achieved low disease activity or remission was significantly higher in the TNFi group compared with the ABT group.
Tapering of anti-TNF therapy can facilitate sustained remission or lower disease activity in most patients with axial spondyloarthritis while ameliorating both risk for adverse events and treatment costs.
A subset of patients with RA fail to respond to tumor necrsis factor (TNF) inhibitor therapy. This study was conducted to evaluate the efficacy of tocilizumab, abatacept and rituximab in these patients.
Methotrexate (MTX) dosage does not impact the efficacy of certolizumab pegol (CZP) in patients with rheumatoid arthritis receiving combination therapy, suggesting that MTX dose modification is feasible without compromising efficacy.
The use of tumor necrosis factor (TNF) inhibitors is associated with an increased risk for a variety of serious infections because TNF-alpha plays a key role in macrophage and phagosome activation, monocyte differentiation into macrophages, and neutrophil recruitment.
The USPSTF concludes with moderate certainty a moderate net benefit in screening at-risk adults for latent tuberculosis infection (LTBI).
Regeneron and Sanofi announced their Phase 3 study for sarilumab has met its primary endpoint, demonstrating superiority over adalimumab in improving symptoms in patients with active rheumatoid arthritis (RA) at Week 24, in the SARIL-RA-MONARCH trials.
Women who received anti-TNF agents during pregnancy did not have a significantly higher risk of having children with birth defects.
There is an increased risk of MS with TNFi therapy, highest in men after the first two years of treatment. This increased risk of MS may be most pronounced and specific to certain cohorts of patients.
Research has identified that certain anti-TNF biologic drugs may confer an elevated risk of MI compared to other medications.
Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune DisordersJanuary 21, 2016
Normal skin tissue morphology restored in psoriatic mice implanted with microencapsulated cytokine converter transgenic designer cells.
The FDA has issued new warnings on the increased incidence of lymphoma among patients receiving golimumab in clinical trials.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care